Literature DB >> 29803828

PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease.

Albert Giralt1, Benoit de Pins2, Carmen Cifuentes-Díaz3, Laura López-Molina4, Amel Thamila Farah5, Marion Tible6, Vincent Deramecourt7, Stefan T Arold8, Silvia Ginés9, Jacques Hugon10, Jean-Antoine Girault11.   

Abstract

Pyk2 is a Ca2+-activated non-receptor tyrosine kinase enriched in forebrain neurons and involved in synaptic regulation. Human genetic studies associated PTK2B, the gene coding Pyk2, with risk for Alzheimer's disease (AD). We previously showed that Pyk2 is important for hippocampal function, plasticity, and spine structure. However, its potential role in AD is unknown. To address this question we used human brain samples and 5XFAD mice, an amyloid mouse model of AD expressing mutated human amyloid precursor protein and presenilin1. In the hippocampus of 5XFAD mice and in human AD patients' cortex and hippocampus, Pyk2 total levels were normal. However, Pyk2 Tyr-402 phosphorylation levels, reflecting its autophosphorylation-dependent activity, were reduced in 5XFAD mice at 8 months of age but not 3 months. We crossed these mice with Pyk2-/- mice to generate 5XFAD animals devoid of Pyk2. At 8 months the phenotype of 5XFAD x Pyk2-/- double mutant mice was not different from that of 5XFAD. In contrast, overexpression of Pyk2 in the hippocampus of 5XFAD mice, using adeno-associated virus, rescued autophosphorylated Pyk2 levels and improved synaptic markers and performance in several behavioral tasks. Both Pyk2-/- and 5XFAD mice showed an increase of potentially neurotoxic Src cleavage product, which was rescued by Pyk2 overexpression. Manipulating Pyk2 levels had only minor effects on Aβ plaques, which were slightly decreased in hippocampus CA3 region of double mutant mice and increased following overexpression. Our results show that Pyk2 is not essential for the pathogenic effects of human amyloidogenic mutations in the 5XFAD mouse model. However, the slight decrease in plaque number observed in these mice in the absence of Pyk2 and their increase following Pyk2 overexpression suggest a contribution of this kinase in plaque formation. Importantly, a decreased function of Pyk2 was observed in 5XFAD mice, indicated by its decreased autophosphorylation and associated Src alterations. Overcoming this deficit by Pyk2 overexpression improved the behavioral and molecular phenotype of 5XFAD mice. Thus, our results in a mouse model of AD suggest that Pyk2 impairment may play a role in the symptoms of the disease.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Mouse model; Non-receptor tyrosine protein kinase; Pyk2; Src

Mesh:

Substances:

Year:  2018        PMID: 29803828     DOI: 10.1016/j.expneurol.2018.05.020

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  13 in total

1.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.

Authors:  Santiago V Salazar; Timothy O Cox; Suho Lee; A Harrison Brody; Annabel S Chyung; Laura T Haas; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2018-12-05       Impact factor: 6.167

2.  Pyk2 Signaling through Graf1 and RhoA GTPase Is Required for Amyloid-β Oligomer-Triggered Synapse Loss.

Authors:  Suho Lee; Santiago V Salazar; Timothy O Cox; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

3.  Conditional BDNF Delivery from Astrocytes Rescues Memory Deficits, Spine Density, and Synaptic Properties in the 5xFAD Mouse Model of Alzheimer Disease.

Authors:  Benoit de Pins; Carmen Cifuentes-Díaz; Amel Thamila Farah; Laura López-Molina; Enrica Montalban; Anna Sancho-Balsells; Ana López; Silvia Ginés; José María Delgado-García; Jordi Alberch; Agnès Gruart; Jean-Antoine Girault; Albert Giralt
Journal:  J Neurosci       Date:  2019-01-30       Impact factor: 6.167

4.  14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.

Authors:  Wenjun Chen; Mengyao Wang; Minzhen Zhu; Wenchao Xiong; Xihe Qin; Xinhong Zhu
Journal:  J Neurosci       Date:  2020-09-24       Impact factor: 6.167

5.  Meridianins Rescue Cognitive Deficits, Spine Density and Neuroinflammation in the 5xFAD Model of Alzheimer's Disease.

Authors:  Ened Rodríguez-Urgellés; Anna Sancho-Balsells; Wanqi Chen; Laura López-Molina; Ivan Ballasch; Ignacio Del Castillo; Conxita Avila; Jordi Alberch; Albert Giralt
Journal:  Front Pharmacol       Date:  2022-02-24       Impact factor: 5.810

6.  The non-receptor tyrosine kinase Pyk2 modulates acute locomotor effects of cocaine in D1 receptor-expressing neurons of the nucleus accumbens.

Authors:  Albert Giralt; Jean-Antoine Girault; Benoit de Pins; Enrica Montalban; Peter Vanhoutte
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

7.  Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice.

Authors:  Li-Xin Jiang; Geng-Di Huang; Feng Su; Huali Wang; Chen Zhang; Xin Yu
Journal:  Psychopharmacology (Berl)       Date:  2020-01-18       Impact factor: 4.530

8.  RTP801/REDD1 contributes to neuroinflammation severity and memory impairments in Alzheimer's disease.

Authors:  Albert Giralt; Cristina Malagelada; Leticia Pérez-Sisqués; Anna Sancho-Balsells; Júlia Solana-Balaguer; Genís Campoy-Campos; Marcel Vives-Isern; Ferran Soler-Palazón; Marta Anglada-Huguet; Miguel-Ángel López-Toledano; Eva-Maria Mandelkow; Jordi Alberch
Journal:  Cell Death Dis       Date:  2021-06-15       Impact factor: 8.469

Review 9.  Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development.

Authors:  Rayan Naser; Abdullah Aldehaiman; Escarlet Díaz-Galicia; Stefan T Arold
Journal:  Cancers (Basel)       Date:  2018-06-11       Impact factor: 6.639

10.  Genetic Association of FERMT2, HLA-DRB1, CD2AP, and PTK2B Polymorphisms With Alzheimer's Disease Risk in the Southern Chinese Population.

Authors:  Yi Yan; Aonan Zhao; Yinghui Qui; Yuanyuan Li; Ran Yan; Ying Wang; Wei Xu; Yulei Deng
Journal:  Front Aging Neurosci       Date:  2020-02-04       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.